BEGIN:VCALENDAR VERSION:2.0 METHOD:PUBLISH PRODID:-//Telerik Inc.//Sitefinity CMS 14.4//EN BEGIN:VTIMEZONE TZID:Central Standard Time BEGIN:STANDARD DTSTART:20231102T020000 RRULE:FREQ=YEARLY;BYDAY=1SU;BYHOUR=2;BYMINUTE=0;BYMONTH=11 TZNAME:Central Standard Time TZOFFSETFROM:-0500 TZOFFSETTO:-0600 END:STANDARD BEGIN:DAYLIGHT DTSTART:20230301T020000 RRULE:FREQ=YEARLY;BYDAY=2SU;BYHOUR=2;BYMINUTE=0;BYMONTH=3 TZNAME:Central Daylight Time TZOFFSETFROM:-0600 TZOFFSETTO:-0500 END:DAYLIGHT END:VTIMEZONE BEGIN:VEVENT DESCRIPTION:Department of Bioethics and Health Humanities \;SeminarCons ent and Withdrawal inPsychedelic ResearchThursday\, December 8\, 202212:00 &ndash\; 1:00 p.m.Emma Tumilty\, PhDAssistant Professor &\; Associate Director of Graduate StudiesDepartment of Bioethics &\; Health Humaniti esMember\, Institute for Bioethics &\; Health HumanitiesSchool of Publi c and Population HealthRegister HERE in advance for the Zoom lectureAfter registering\, you will receive a confirmation email. \;There is a burg eoning psychedelic medicine research field (and related industry) explorin g a range of psychedelic interventions for various mental health condition s. The environment is saturated with hype (and misinformation) and controv ersy. While some of these interventions currently look promising\, much of the interventional evidence generated to date is low to moderate quality. Whistleblowers have recently disclosed questionable research practices in addition to lasting harms from clinical misconceptions\, boundary violati ons\, and serious malpractice by trial therapists (including post-trial cr iminal actions). In this talk\, I will describe the range of ethical issue s arising in this complex research environment and the challenges for rese archers and those reviewing this work. I then focus on what I think is the most pressing issue: consent. I discuss three aspects of consent in the p sychedelic research process: enrolment\, issues of touch\, and session/res earch withdrawal. I discuss whether dynamic consent processes can improve ethical practice here \, as well as describe a precautionary principle app roach to touch and withdrawal. Challenges in managing these processes and overseeing their management are described. Psychedelic medicine may provid e a much needed effective intervention for mental illnesses for some peopl e. The current environment surrounding psychedelic medicine makes the robu st and ethical exploration of their efficacy difficult. Further awareness and discussion is needed from researchers and regulators to address the di fficulties specific to this setting. Problems left unaddressed (or suppres sed) in the research environment are likely to be magnified and multiplied in clinical settings and so there is an urgent need to get this work righ t\, ethically\, scientifically\, and clinically. DTEND:20221208T190000Z DTSTAMP:20240329T101851Z DTSTART:20221208T180000Z LOCATION: SEQUENCE:0 SUMMARY:Consent and Withdrawal in Psychedelic Research UID:RFCALITEM638472863314570300 X-ALT-DESC;FMTTYPE=text/html:
Emma Tumilty\, PhD
Assistant Pr
ofessor &\; Associate Director of Graduate Studies
Department of B
ioethics &\; Health Humanities
Member\, Institute for Bioethics &a
mp\; Health Humanities
School of Public and Population Health
Register HERE in advance for the Zoom lecture p>
After registering\, you wi ll receive a confirmation email.
 \;
There is a burgeoning psychedelic medicine research field (and related industry) exploring a ra nge of psychedelic interventions for various mental health conditions. The environment is saturated with hype (and misinformation) and controversy. While some of these interventions currently look promising\, much of the i nterventional evidence generated to date is low to moderate quality. Whist leblowers have recently disclosed questionable research practices in addit ion to lasting harms from clinical misconceptions\, boundary violations\, and serious malpractice by trial therapists (including post-trial criminal actions).
In this talk\, I will describe the range of ethical issu es arising in this complex research environment and the challenges for res earchers and those reviewing this work. I then focus on what I think is th e most pressing issue: consent. I discuss three aspects of consent in the psychedelic research process: enrolment\, issues of touch\, and session/re search withdrawal. I discuss whether dynamic consent processes can improve ethical practice here \, as well as describe a precautionary principle ap proach to touch and withdrawal. Challenges in managing these processes and overseeing their management are described.
Psychedelic medicine ma y provide a much needed effective intervention for mental illnesses for so me people. The current environment surrounding psychedelic medicine makes the robust and ethical exploration of their efficacy difficult. Further aw areness and discussion is needed from researchers and regulators to addres s the difficulties specific to this setting. Problems left unaddressed (or suppressed) in the research environment are likely to be magnified and mu ltiplied in clinical settings and so there is an urgent need to get this w ork right\, ethically\, scientifically\, and clinically.
END:VEVENT END:VCALENDAR